What Is PEG-MGF? The Pegylated IGF-1 Splice Variant Explained

Reviewed by Thomas Okafor, Peptide Chemist · Updated October 2026

PEG-MGF is a lab-made version of mechano growth factor, a 24-amino-acid piece of a muscle-specific form of IGF-1 that the body makes more of after exercise or injury. The “PEG” is polyethylene glycol, a chain attached to slow the molecule’s breakdown. It’s studied for muscle repair, with most of that work in cells and animals.

MGF’s story is unusually contested. The original findings came from one London research group in the late 1990s and 2000s, and a 2014 replication attempt by scientists at two pharmaceutical companies found no effect on muscle cells at all. No human trial of MGF or PEG-MGF has been published as of October 2026.

PEG-MGF isn’t approved for any use, and research-grade PEG-MGF is sold for research use only. This guide is educational; see our Medical Disclaimer.

What Is PEG-MGF?

PEG-MGF starts with the IGF-1 gene. That gene can be read in several ways, producing different versions of the IGF-1 protein. One version, called IGF-1Ec in humans, has an extra stretch of genetic code that changes how the rest is read, creating a distinctive tail. Geoffrey Goldspink’s group at University College London named that version mechano growth factor, because muscle made more of it after mechanical loading.

The peptide itself. When the body processes IGF-1Ec, the mature IGF-1 hormone is cleaved from the tail. The last 24 amino acids of that tail are what research vials sell as MGF. It’s a fragment, not IGF-1, and it doesn’t bind the IGF-1 receptor.

Why pegylation. Plain MGF breaks down in blood within minutes. Attaching polyethylene glycol, a long inert chain, is a standard pharmaceutical trick that shields a molecule from enzymes and kidney clearance. PEG-MGF was built by people selling research peptides, not by a drug company, and no published study has measured how long it actually lasts in a person.

The contested evidence. Goldspink’s group reported that MGF activated muscle stem cells, and a 2011 study with his collaborators in Paris found the peptide extended the growing life of muscle precursor cells from young donors, though not from older ones. Then researchers at Novartis and GSK tried to reproduce the basic finding.

Also known as: MGF, IGF-1Ec and the E peptide

MGF and mechano growth factor are the same thing. IGF-1Ec is the human splice variant the peptide comes from, and IGF-1Eb is the rodent equivalent, which is why animal papers use different names. “MGF C-terminal E peptide” or “MGF-24aa-E” appear in the research literature. PEG-MGF specifically means the pegylated form.

How Does PEG-MGF Work?

The proposed mechanism is that MGF activates satellite cells, the stem cells that rest alongside muscle fibers and repair them after damage, and holds them in a dividing state longer before they fuse into fibers. More dividing cells would mean more raw material for repair. The receptor behind this hasn’t been identified, which is a notable gap.

What’s known, and from what kind of research:

• Exercise response (human tissue): IGF-1Ec messenger RNA rises in human muscle after resistance exercise and damage, which is the observation that started the field.
• Satellite cell effects (lab, disputed): the 2011 Paris study found MGF-E increased the proliferative lifespan of muscle precursor cells from young donors. A 2014 study run jointly at Novartis and GSK found no effect on mouse or human myoblast proliferation at concentrations up to 500 ng/ml.
• No IGF-1 receptor binding (lab): MGF doesn’t act through the IGF-1 receptor, so whatever it does works by another route.
• Heart and nerve protection (animal): MGF reduced loss of heart function after induced heart attack in animals, and improved motor neuron survival in a mouse model of ALS.
• Pegylation (inferred): PEG chains extend half-life for approved drugs. For PEG-MGF, this is reasoning from chemistry, not measurement.

What does PEG-MGF do? Think of a construction site where damage calls in extra workers. MGF is proposed as the message that calls them and keeps them on the job before they settle into place. Whether an injected fragment delivers that message is exactly what the conflicting studies disagree about.

What Is PEG-MGF Used For / Studied For?

PEG-MGF is studied for muscle repair and growth, with smaller lines of work on heart injury, nerve protection and cartilage. Every published study is in cells or animals. Online it’s marketed for recovery and muscle gain, which no human research supports.

Muscle repair and growth

What was studied: cultured mouse and human muscle cells, rodent muscle injury and overload models, and measurements of natural IGF-1Ec in people after exercise.

What it found: the London group’s work reported satellite cell activation and larger muscle in rodents. The 2011 Paris study found effects in cells from young but not old donors.

What it doesn’t show: a reproducible effect on muscle cells. The 2014 pharmaceutical-industry attempt, using both mouse and human cells, found no increase in proliferation, which the authors noted contradicted the earlier claims.

Heart injury

What was studied: animal models of heart attack, where MGF or a synthetic E-domain peptide was given after the injury.

What it found: reduced loss of heart function in those models.

What it doesn’t show: any human cardiac data. These results haven’t moved into clinical testing.

Nerve and motor neuron protection

What was studied: mouse models of ALS and cultured nerve cells.

What it found: MGF improved motor neuron survival and muscle function in a mouse ALS model, and affected nerve fiber growth in culture.

What it doesn’t show: benefit in people with any neurological condition.

What PEG-MGF hasn’t been shown to do

It hasn’t been shown to build muscle, speed injury recovery, improve athletic performance or heal tendons in people. It also hasn’t been shown to last longer in the body than plain MGF, despite that being the whole point of adding the PEG chain.

What Does the Human Research Show?

There are no published human trials of MGF or PEG-MGF. Human involvement in this literature is limited to two things: muscle biopsies showing that natural IGF-1Ec rises after exercise, and lab experiments on muscle cells taken from human donors, which have produced conflicting results.

PubMed and ClinicalTrials.gov searched October 5, 2026. No registered trial of MGF or PEG-MGF in people was found.

Why the disagreement counts. A failed replication by two pharmaceutical companies, which had a commercial reason to want MGF to work, is a meaningful signal. It doesn’t prove MGF does nothing, but it means the foundation under the online claims is shakier than those claims suggest. A 2026 review of performance peptides from Poznań University groups MGF with other unregulated compounds people self-administer without clinical evidence. Our Editorial Policy explains how we weigh replication failures.

PEG-MGF Side Effects and Safety

PEG-MGF’s safety in people is unknown, because no human study exists. The concerns are theoretical and come from two directions: what growth factors do to cells that are already growing abnormally, and what repeated pegylated injections do over time.

Reported in human studies: none; no human trials have been published.

Expected from the mechanism: anything that encourages cells to divide raises questions for people with cancer or precancerous conditions. MGF doesn’t bind the IGF-1 receptor, so the specific IGF-1 cancer concerns don’t transfer directly, but its own receptor is unknown, which makes the risk harder to reason about, and not smaller.

Pegylation itself: PEG is used safely in approved drugs, though some people develop anti-PEG antibodies, and PEG can accumulate in tissues with repeated dosing. For approved drugs these risks are monitored. For a research chemical, the PEG chemistry, chain length and attachment site aren’t disclosed or standardized.

Anecdotal only: people using research-grade PEG-MGF online report injection-site swelling and lumps, headaches and tiredness. Many describe being unable to tell whether it did anything. None of this has been studied.

Product quality: pegylation adds a manufacturing step that ordinary purity testing handles poorly, since a certificate may report the peptide’s purity without confirming the PEG chain is attached where it should be. Our peptide COA guide covers what these documents can verify.

Who should avoid PEG-MGF

Anyone with active or past cancer has the clearest reason to avoid it. So do people who are pregnant or breastfeeding, anyone under 18, and athletes in tested sport, where mechano growth factors are explicitly banned.

PEG-MGF vs IGF-1 LR3

PEG-MGF and IGF-1 LR3 both come from the IGF-1 gene but are different molecules with different evidence. IGF-1 LR3 is a modified version of the full IGF-1 hormone that binds the IGF-1 receptor. PEG-MGF is a 24-amino-acid tail fragment that doesn’t.

Our IGF-1 LR3 guide covers how that molecule’s half-life claims compare with the published data.

Is PEG-MGF Legal?

PEG-MGF isn’t FDA-approved for any use. Mechano growth factor is in the FDA’s 503A Category 3, meaning it was nominated for compounding but the submission lacked enough information to evaluate. The separate PEG-MGF nomination was withdrawn. WADA bans mechano growth factors in sport at all times.

FDA. Category 3 isn’t a safety verdict; it means the FDA couldn’t assess the substance from what was submitted. Either way, pharmacies can’t compound with it. MGF wasn’t among the peptides reviewed at the July 2026 Pharmacy Compounding Advisory Committee meeting.

Research use only. Products sold this way haven’t been evaluated for human use. Our guide to whether research peptides are legal explains the rules.

Sport. The 2026 WADA Prohibited List names “mechano growth factors (MGFs)” under S2, among growth factors and growth factor modulators, banned in and out of competition.

FDA and WADA status checked October 5, 2026.

Where PEG-MGF Fits: Needs & Symptoms

PEG-MGF appears in Recovery & Tissue Repair, described as a modified IGF-1 splice variant studied for its localized role in muscle-tissue repair signaling. “Localized” is accurate to the original theory: MGF was described as acting where muscle was damaged, not body-wide.

Related guides in that category include follistatin 344, which targets the myostatin brake and does have small human trials, TB-500 for tissue repair, and IGF-1 LR3.

Frequently Asked Questions

What is PEG-MGF?

PEG-MGF is a lab-made, pegylated copy of mechano growth factor, a 24-amino-acid fragment from a muscle-specific form of IGF-1 that rises after exercise or injury.

Is PEG-MGF the same as IGF-1?

No. It’s a small tail fragment left over when IGF-1Ec is processed, and it doesn’t bind the IGF-1 receptor. IGF-1 itself is a different, much larger molecule.

Does PEG-MGF build muscle?

No human study has tested it. Cell and animal results conflict, and a 2014 replication attempt by two pharmaceutical companies found no effect on muscle cells.

What does the PEG do?

Polyethylene glycol is attached to slow breakdown. That’s standard for approved drugs, but no published study has measured how long PEG-MGF lasts in people.

Is PEG-MGF safe?

Unknown. There are no human trials. Theoretical concerns involve cell growth in people with cancer, and the effects of repeated pegylated injections.

Is MGF banned in sports?

Yes. WADA’s 2026 list names mechano growth factors under section S2, banned in and out of competition.

Why is MGF in FDA Category 3?

Category 3 means the nomination for compounding didn’t include enough information for the FDA to evaluate it. The separate PEG-MGF nomination was withdrawn.

How much PEG-MGF should be used?

There’s no research-based dosing for non-approved use, and we don’t publish dosing for any compound. See our Medical Disclaimer.

Disclaimer: PEG-MGF isn’t approved for any use, and research-grade PEG-MGF is sold for research use only. This guide is educational and doesn’t give medical advice. Read our Medical Disclaimer and Editorial Policy.